{"type":"trials","record":{"id":86138,"source_id":"isrctn","external_id":"ISRCTN28276860","title":"Can deep phenotyping using retinal images predict response to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration?","brief_summary":"Can artificial intelligence predict treatment response with aflibercept for neovascular age-related macular degeneration better than human graders?","overall_status":"Completed","phases":[],"study_type":"Observational","sponsor":"Moorfields Eye Hospital","enrollment":2128,"countries":["United Kingdom","England"],"start_date":"2019-12-01","completion_date":"2022-06-30","last_update_date":"2026-09-22","source_url":"https://www.isrctn.com/ISRCTN28276860","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:45:21.717702+00:00","last_seen_at":"2026-09-26T12:27:04.896+00:00","metadata":{"sex":"All","age_range":"Adult","comparator":null,"attribution":"Source: ISRCTN ISRCTN28276860; retrieved 2026-09-26","interventions":["Other"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["Diagnostic accuracy of artificial intelligence over human graders in assessing the response of loading phase of intravi…","1. The analyses will be repeated excluding patients who appeared in the training set and the primary validation set 2.…"],"design_description":"Observational","source_has_results":false},"controlled_terms":["Wet age-related macular degeneration","The OCT and OCTA images taken at baseline and various time points until after the third aflibercept injection for wet A…","PRECISE Study Report 1: primary results","PRECISE study report 3: baseline characteristics in patients with and without early residual fluid","PRECISE Report 5: impact of definitions of various treatment extension criteria on the proportion of patients who could…","PRECISE Report No. 6: first dose versus three monthly doses of 2 mg aflibercept","PRECISE Study Report 2: identify baseline OCT features that best explain presenting VA in nAMD","PRECISE Study Report 7: Factors associated with outcomes during loading doses","PRECISE Study Report 9: BALAD prevalence, baseline clinical characteristics and the visual and anatomical response","Protocol file","Other"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-26T12:27:05.193853+00:00","duplicate_cluster_key":"id:isrctn28276860","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-12-01 to 2022-06-30","comparator":null,"confidence":"structured-source","population":"All · Adult","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-26T12:27:04.899Z","intervention":["Other"],"participants":2128,"study_design":"Observational","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Diagnostic accuracy of artificial intelligence over human graders in assessing the response of loading phase of intravi…","1. The analyses will be repeated excluding patients who appeared in the training set and the primary validation set 2.…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Observational."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/86138","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}